Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

173
Delayed Quote. Delayed BATS EUROPE - 10/24 05:30:00 pm
85.7500 CHF   0.00%
3d agoDJNovartis 3Q 2014 -- Forecast
3d ago NOVARTIS : reports positive results in spinal inflammation condition
3d ago NOVARTIS : AIN457 (secukinumab) meets primary endpoint in two Phase III stu..
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
10/20/2014 10/21/2014 10/22/2014 10/23/2014 10/24/2014 Date
82.8(c) 83.55(c) 84.65(c) 85.4(c) 85.75(c) Last
5 833 958 6 657 199 4 485 797 4 809 207 4 100 733 Volume
+0.73% +0.91% +1.32% +0.89% +0.41% Change
More quotes
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
Surperformance© rating of Novartis AG
Trading Rating : Investor Rating :
More about the company
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 59 015 M
EBIT 2014 13 909 M
Net income 2014 10 474 M
Debt 2014 5 135 M
Yield 2014 2,99%
Sales 2015 57 557 M
EBIT 2015 14 521 M
Net income 2015 11 354 M
Debt 2015 8 254 M
Yield 2015 3,18%
PER 2014 21,22
PER 2015 19,61
EV / Sales 2014 4,21x
EV / Sales 2015 4,37x
Capitalization 243 245 M
More Financials
Latest news on NOVARTIS AG
3d agoDJNovartis 3Q 2014 -- Forecast
3d ago NOVARTIS : Patent Issued for Devices and Methods for Holding an Intraocular Lens..
3d ago NOVARTIS : reports positive results in spinal inflammation condition
3d ago NOVARTIS : FDA Advisory Committee Recommends Approval of AIN457 (secukinumab) fo..
3d ago NOVARTIS : AIN457 (secukinumab) meets primary endpoint in two Phase III studies ..
3d ago NOVARTIS : AIN457 (secukinumab) meets primary endpoint in two Phase III studies ..
3d ago NOVARTIS : AIN457 (secukinumab) meets primary endpoint in two Phase III studies ..
3d ago NOVARTIS : Patent Application Titled "Automated Intraocular Lens Injector Device..
4d ago NOVARTIS : announces CTL019 data published in NEJM demonstrating efficacy in cer..
4d ago GSK eyes prime FTSE 100 slot for standalone HIV drugs business
4d ago NOVARTIS : teams up with multiple sclerosis advocate and musician David Osmond t..
4d ago Glaxo Holds Full Year Expectations, But Launches New Restructuring
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF